0.78
-0.01265(-1.59%)
Currency In USD
| Previous Close | 0.79 |
| Open | 0.72 |
| Day High | 0.84 |
| Day Low | 0.72 |
| 52-Week High | 19.2 |
| 52-Week Low | 0.72 |
| Volume | 31,621 |
| Average Volume | 77,524 |
| Market Cap | 5.61M |
| PE | 2.17 |
| EPS | 0.36 |
| Moving Average 50 Days | 1.02 |
| Moving Average 200 Days | 2.7 |
| Change | -0.01 |
If you invested $1000 in Calidi Biotherapeutics, Inc. (CLDI) since IPO date, it would be worth $8 as of March 03, 2026 at a share price of $0.782. Whereas If you bought $1000 worth of Calidi Biotherapeutics, Inc. (CLDI) shares 3 years ago, it would be worth $7.62 as of March 03, 2026 at a share price of $0.782.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference
GlobeNewswire Inc.
Feb 20, 2026 1:00 PM GMT
SAN DIEGO, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today presented data on its novel approac
Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference
GlobeNewswire Inc.
Feb 12, 2026 1:00 PM GMT
SAN DIEGO, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, today announced that it will present data
Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026
GlobeNewswire Inc.
Jan 28, 2026 1:00 PM GMT
Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the tumor microenvironment in patients